Elekta AB Unsponsored ADR Class B ( (EKTAY) ) has released its Q1 earnings. Here is a breakdown of the information Elekta AB Unsponsored ADR Class B presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Elekta AB Unsponsored ADR Class B is a leading company in the medical technology sector, specializing in innovative solutions for radiation therapy and radiosurgery used in cancer treatment. The company is known for its cutting-edge products like the Elekta Evo linear accelerator and the Leksell Gamma Knife.
In its first quarter report for the fiscal year 2025/26, Elekta AB highlighted a 3% increase in net sales at constant exchange rates, primarily driven by strong performance in Europe. Despite a reported sales decrease of 5% in SEK, the company showed improved cash flow and continued strong order growth for its Elekta Evo product.
Key financial metrics revealed a lower adjusted gross margin of 37.0% due to foreign exchange and tariff costs, while adjusted EBIT was SEK 235 million, down from SEK 283 million the previous year. However, net income rose significantly by 50% to SEK 106 million, and earnings per share increased by 52% to SEK 0.28. The company also reported a substantial improvement in cash flow after investments, driven by effective working capital management.
Looking forward, Elekta’s management remains optimistic about achieving its mid-term financial goals, including restoring gross margins to pre-pandemic levels and reaching an EBIT margin of at least 14%. The company anticipates challenges in the US and China markets in the short term but expects recovery in the latter half of the fiscal year.
Elekta’s strategic focus on product innovation and market expansion, coupled with its commitment to operational excellence, positions it well for future growth despite current market challenges.